Chief Executive Officer
John joins FPWR having served as CEO for the Alliance for Cancer Gene Therapy a research foundation that exclusively supports research in genetic, cell and immunotherapeutic approaches to improve outcomes for all cancers. Prior, John served as President and CEO of the Leukemia & Lymphoma Society, a $300 million international health agency. He drove LLS’s long-range strategic plan with a focus on broadening its base of support and diversifying its revenue sources. John augmented the society’s research portfolio to include venture philanthropy with direct investments into bio-tech companies. John joined LLS in 1995 as Senior Vice President of Finance and Information Technology. Later, as Executive Vice President of Strategic Alliances, he designed and implemented LLS’s Co-Pay Assistance Program, which has provided more than $200 million to patients since inception. He also oversaw the international merger that created LLS Canada. He was appointed CEO in Feb 2008. John has spoken at congressional events in Washington, and to the international business community.